Saghmos Therapeutics Inc. announced the issuance of the U.S. Patent No. 11,123,345 for its product ST-62516, also known as trimetazidine, along with its plans for a phase 3 study of the drug.“This patent lays the foundation for Saghmos’ growing intellectual property estate, including pending international patents, as well as additional patent applications that are in